Results 301 to 310 of about 143,596 (340)

A potential risk factor for paraoxonase 1: in silico and in‐vitro analysis of the biological activity of proton‐pump inhibitors

The Journal of pharmacy and pharmacology, 2019
Proton‐pump inhibitors (PPIs) are drugs commonly utilized by about 7% of adults in the world. Recent researches have shown that there are countless and severe side effects of these drugs.
Cüneyt Türkeş
semanticscholar   +1 more source

Proton Pump Inhibitors

Reactions Weekly, 2017
Guidelines generally recommend proton pump inhibitors (PPIs) over histamine type 2 receptor antagonists when acid suppression is advocated because of a longer duration of action, a superior ability in reducing acid secretion, and the absence of tachyphylaxis with repeated dosing.
Licia Pensabene, Geoffrey Davidson
openaire   +2 more sources

Proton pump inhibitors

BMJ, 2023
Danny, Jenkins, Ines, Modolell
openaire   +2 more sources

Relationship between long‐term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis

Journal of Gastroenterology and Hepatology, 2019
This study aims to systematically analyze the effect of long‐term therapy with proton pump inhibitors (PPIs) on the risk of gastric cancer.
Kailin Jiang, Xiaotao Jiang, Yi Wen, Liu Liao, Fengbin Liu   +4 more
semanticscholar   +1 more source

Deprescribing Proton Pump Inhibitors

JAMA Internal Medicine, 2020
Jacob E, Kurlander, Juan J, Gonzalez, Sameer D, Saini   +2 more
openaire   +4 more sources

Proton pump inhibitors

British Dental Journal, 2010
  +5 more sources

The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.

Gastroenterology, 2017
D. Freedberg, Lawrence S. Kim, Yu-Xiao Yang   +2 more
semanticscholar   +1 more source

▼Lansoprazole - another proton pump inhibitor

Drug and Therapeutics Bulletin, 1995
Lansoprazole (Zoton - Lederle) is a proton pump inhibitor recently licensed for the treatment of duodenal ulcer, benign gastric ulcer or reflux oesophagitis. It is structurally related to omeprazole, which has now been available in the UK for 6 years. In this article we consider the place of lansoprazole in the treatment of patients with acid-related ...
openaire   +2 more sources

Proton Pump Inhibitors

Clinical Gastroenterology and Hepatology, 2006
  +5 more sources

Elastocaloric heat pump with specific cooling power of 20.9 W g–1 exploiting snap-through instability and strain-induced crystallization

Nature Energy, 2021
Guoyong Mao, Nikita Arnold, Martin Kaltenbrunner   +2 more
exaly